Applications deadline: November 1
P&G Ventures is looking for startup submissions on disruptive solutions in women's wellness. P&G is on a mission to help women (18+) optimize/enhance their health and wellness by (a) creating products that are designed specifically for women, (b) address gaps in her self-care and (c) offer meaningful difference in her life. We will start by addressing frequent, daily fatigue that negatively impacts her day, her capacity and ultimately her relationships.
P&G and AS Watson are looking for startup partnerships to build new, personalized, effortless, and cost-effective ways to enhance the overall shopper experience Online + Offline through the Guided Selling Challenge and the Social Commerce Challenge.
Looking for 8-10 startups to present their tech on April 12 at the 2022 MIT Health Science Technologies Conference: The Future of Cell & Gene Therapies.
P&G is looking to understand the broad external ecosystem in the Future of Home space to assess potential new business opportunities and partnerships to accelerate innovation that is sustainable, smart, and delightful to consumers. We are looking for existing labs that are experimenting around the future of home or technology providers that have access to or could help us create a lab environment.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
Nissan Chemical Corporation is developing new manufacturing systems of large quantities of cell spheroids for regenerative medicines and drug discoveries and are now seeking potential collaborators for development of new applications of this system.